title: Realgar (As4S4) nanoparticles and arsenic trioxide (As2O3) induced autophagy and apoptosis in human melanoma cells in vitro.
abstract: The aim of the present study was to compare the effect of realgar nanoparticles and arsenic trioxide (ATO) on viability, DNA damage, proliferation, autophagy and apoptosis in the human melanoma cell lines BOWES and A375. The application of various flow cytometric methods for measurements cell viability, DNA cell cycle, mitochondrial potential, lysosomal activity, and intracellular content of glutathione was used. In addition, quantitative PCR, western blotting and multiplex bead array analyses were applied for evaluation of redox stress, autophagic flux, and cell signaling alterations.The results showed that realgar treatment of studied cells caused modulation of cell proliferation, induced a block in G2/M phase of the cell cycle and altered phosphorylation of IκB, Akt, ERK1/2, p38, and JNK kinases, as well as decreased mitochondrial membrane potential. Additionally, it appeared that induction of cell death by both realgar and ATO was dose-dependent, when lower (0.3 µM) dosage increased lysosomal activity and induced autophagy and higher (1.25 µM) concentration resulted in the appearance of apoptosis, while pan-caspase inhibitor attenuated more efficiently realgar- than ATO-induced cell death. Furthermore, low concentrations of ATO and realgar nanoparticles increased the content of intracellular glutathione and elevated γ-H2AX expression confirmed DNA damage preferentially at higher concentrations of both drugs used. Further analysis revealed slight differences in time-dependent phosphorylation pattern due to both realgar and ATO treatments, while significant differences were noticed between cell lines. In conclusion, realgar nanoparticles and ATO treatment induced dose-dependent activation of autophagy and apoptosis in both melanoma cell lines, when autophagy flux was determined at lower drug concentrations and the switch to apoptosis occurred at higher concentrations of both arsenic forms.
authors.forename: M
authors.initials: M
authors.lastname: Pastorek
authors.forename: P
authors.initials: P
authors.lastname: Gronesova
authors.forename: D
authors.initials: D
authors.lastname: Cholujova
authors.forename: L
authors.initials: L
authors.lastname: Hunakova
authors.forename: Z
authors.initials: Z
authors.lastname: Bujnakova
authors.forename: P
authors.initials: P
authors.lastname: Balaz
authors.forename: J
authors.initials: J
authors.lastname: Duraj
authors.forename: T C
authors.initials: TC
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: Sedlak
mesh_terms: D000590:Amino Acid Chloromethyl Ketones / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D001343:Autophagy / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002738:Chloroquine / Q000494:pharmacology; D004249:DNA Damage; D005978:Glutathione / Q000032:analysis; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D053758:Nanoparticles; D010087:Oxides / Q000494:pharmacology*; D010766:Phosphorylation; D013440:Sulfides / Q000494:pharmacology*
chemical_list: D000590:Amino Acid Chloromethyl Ketones; D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D013440:Sulfides; C096713:benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; C058317:arsenic disulfide; D002738:Chloroquine; D005978:Glutathione; D000077237:Arsenic Trioxide